Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COX-2s Left Out Of Drug Classes, Will Go Up Against Other NSAIDs

This article was originally published in The Pink Sheet Daily

Executive Summary

COX-2 inhibitors are among the drugs where Medicare coverage would be "recommended," but not required, under the U.S. Pharmacopeia's model formulary

You may also be interested in...



CMS Medicare Formulary Standards Will Have More “Granularity” Than USP

The Centers for Medicare & Medicaid Services expects its reviews of Medicare Rx drug plan formularies to include evaluation of drug choices at the “sub-class” level. The standards will also aim to encourage plans to provide more than the minimum two drugs per formulary class.

CMS Medicare Formulary Standards Will Have More “Granularity” Than USP

The Centers for Medicare & Medicaid Services expects its reviews of Medicare Rx drug plan formularies to include evaluation of drug choices at the “sub-class” level. The standards will also aim to encourage plans to provide more than the minimum two drugs per formulary class.

Cardiovascular Category Has 11 Classes, But Statins Not Among Them

Medicare drug formularies would not be required to cover a minimum number of cholesterol-lowering statin drugs under the U.S. Pharmacopeia's proposed model guidelines.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060330

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel